Insider buying last 90 days
No open-market insider purchases were filed for ANIP in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ANIP insider filing, plotted on the chart in Gekko.Open ANIP in Gekko
NASDAQ: ANIP
ANI Pharmaceuticals (ANIP) Stock Analysis & Forecast
Oct 12 close
$73.59−0.30 (−0.4%)
Gekko Brief
AI summaryOct 12 closeANI Pharmaceuticals this week reported positive results from its Phase 4 SYNCHRONICITY trial for its Fluocinolone Acetonide Intravitreal Implant, with both six-month endpoints met, a mean vision gain of 3.6 letters, and reduced central retinal thickness, improvements maintained through 24 months. The open-label, single-arm data were presented as a late-breaking oral presentation at the American Academy of Ophthalmology 2026 Annual Meeting. Separately, coverage noted a consensus price target of $98.00 against a quoted price of $71.93, alongside confirmation that ANI's Q3 2026 earnings are scheduled for 6 November 2026.
ANIP closed at $73.59, down 0.4%, sitting below both its 50-day average of $74.45 and 200-day average of $78.24, with the 50-day below the 200-day. The GekkoIndex reads 57.1, placing the stock in the Neutral zone, down 3.8 over five days. Price sits 40.6% below Gekko Fair Value of $123.93. Over the trailing year the stock is down 18.9%, though the one-month return is up 4.8%.
The next earnings date falls on 6 November 2026, before the open, 25 days away and within a typical 20-trading-day holding window; the prior report on 7 August 2026 produced an 8.3% reaction despite a beat. No insider, Congress, or options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged a 12.9% gain over 5 years, rising in 5 of them. Analyst coverage from 8 firms shows 6 buy and 2 hold ratings, with a consensus target of $105.78.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
ANI Pharmaceuticals price vs fair value
Close $73.59200-day averageGekko Fair Value $123.93
ANI Pharmaceuticals quick facts
- Market cap
- $1.67B
- P/E ratio
- 15.6
- Forward P/E
- 7.1
- EPS, TTM
- $4.62
- Revenue, TTM
- $978.4M
- Profit margin
- 11.1%
- Dividend yield
- —
- Beta
- 0.50
- Volume
- 315,781 avg 422,390
- 1-year return
- −18.9%
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±6.4%
- 50-day average
- $74.45
- 200-day average
- $78.24
- Next earnings
- Nov 6 before open
- Shares outstanding
- 22.96M
ANI Pharmaceuticals swing-trade checklist
ANI Pharmaceuticals scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $73.59 is below the 50-day ($74.45) and 200-day ($78.24) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
57.1, Neutral
Reading 57.1 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
40.6% below
Price is 40.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 25 days
Reports on Nov 6, 2026, 25 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+12.9% on average
From this point in the calendar, the next 20 trading days averaged +12.9% over 5 years, rising in 5 of them.
See seasonality
A description of current data, not a recommendation. How this page works
ANI Pharmaceuticals stock chart and price history
ANI Pharmaceuticals closed at $73.59 on Oct 12, 2026, −18.9% over the past year, inside a 52-week range of $69.58 to $97.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +4.8%
- 3 months
- −8.6%
- 6 months
- −6.0%
- 1 year
- −18.9%
The full ANIP chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ANIP in Gekko
Follow ANI Pharmaceuticals through every session
Put ANIP on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ANIP in GekkoFree for 7 days. No credit card required.
About ANI Pharmaceuticals
ANI Pharmaceuticals works in the biopharmaceutical space, creating, producing and selling both branded and generic medicines across the United States and in other countries. Its lineup includes injectable treatments, softgel capsules, and the Cortrophin gel line, along with the ILUVIEN and YUTIQ products. Beyond these, the company is known for manufacturing a wide range of dosage forms such as oral solids, semi-solids, liquids, topical treatments, and products involving controlled substances.
The business reaches the market through several channels, supplying national wholesalers, specialty and retail pharmacy chains, distributors, mail order operations, group purchasing organizations, and hospitals along with other healthcare providers. This spread of customers reflects a distribution model built around both pharmaceutical supply chains and direct healthcare settings.
The company traces its incorporation back to 2001 and operates out of Baudette, Minnesota. Its shares are listed on the NASDAQ under the ticker ANIP.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- anipharmaceuticals.com
ANI Pharmaceuticals GekkoIndex: the smart money zone
ANI Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.1, in the Neutral zone, down 3.8 points over five sessions.
57.1Neutral
Down 3.8 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 16 | +3.8% | +5.9% | ||
| Accumulation | 250 | +1.2% | +1.6% | ||
| Neutral (current zone) | 383 | −0.5% | +0.6% | ||
| Distribution | 25 | +1.7% | +1.9% | ||
| Selling | 8 | Too few readings yet | |||
Average ANIP share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ANIP price, zone by zone.Track ANIP in Gekko
Is ANI Pharmaceuticals stock overvalued? Gekko Fair Value
ANI Pharmaceuticals trades 40.6% below Gekko Fair Value of $123.93, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ANI Pharmaceuticals shares are worth, recalculated every trading day.
$123.93
Gekko Fair Value, Oct 10, 2026
40.6% Undervalued
At the end of Aug 2026 the price was 25.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ANIP in Gekko
ANI Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for ANI Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ANIP were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ANIP, plotted on the chart in Gekko.Open ANIP in Gekko
Buybacks
ANI Pharmaceuticals has been buying back its own shares.
- Latest authorization
- $100.0M, Aug 7, 2026
- Bought back, quarter ended Jun 30, 2026
- $813K
- As a share of market cap
- 0.05%
- Trailing four quarters
- $22.22M
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold ANIP.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
ANI Pharmaceuticals earnings: next date and track record
ANI Pharmaceuticals reports on Nov 6, 2026, before the open (25 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Nov 6, 2026
Expected before the open, 25 days away
- EPS estimate
- $2.18
- Revenue estimate
- $280.3M
7 of 8reports beat the EPS estimate
±8.4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 7, 2026 AI summary
- What they said
- ANI reported strong second quarter 2026 results and reiterated confidence in its transformation into a rare disease–focused company. Management highlighted record Q2 net revenues of $266.0 million, record Cortrophin revenues of $117.1 million (up 43% y/y), and record adjusted EBITDA of $71.6 million (up 32% y/y). Growth was driven by performance across Rare Disease and Generics and incremental revenue from a Harmony out-licensing deal. Management completed a 50% increase in the rare disease sales force (to ~180 reps) and launched a gout-targeted commercial expansion. Cortrophin momentum continued in existing specialties (notably ophthalmology) and early indicators from the gout expansion are positive (high percentage of reps generating multiple new cases, growth in new patient starts in July). CFO commentary was factual on revenue mix: Generics up 10% y/y, ILUVIEN down 16% y/y (timing), non-GAAP gross margin down ~230 bps to 62.6% due to product mix, and non-GAAP R&D down 11% while SG&A increased 20% due to the sales expansion. Management reiterated full-year revenue expectations (> $1 billion) and expects Rare Disease to approach ~60% of revenues in 2026. Q&A focused on gout uptake, payer reverification issues (noted as largely resolved), timing of revenue from the sales force expansion, IQVIA data disconnects, vial-per-patient dynamics, time-to-fill, and potential M&A opportunities to leverage the larger commercial footprint.
- Guidance
- - Full-year 2026 revenue target: expected to deliver over $1 billion in revenue. - Rare Disease expected to approach ~60% of total revenues in 2026. - Cortrophin full-year 2026 guidance: $520 million to $540 million (50% to 55% y/y growth expected). - Q3 2026 Cortrophin guidance: $143 million to $153 million. - Expect to recognize the remaining ~$2 million of the Harmony-related development milestone in Q3 2026. - Management said they are confident in achieving their 2026 financial guidance and expect meaningful back-half contribution from the gout sales force expansion.
- Risks flagged
- - Prior authorization/patient reverification disruptions (noted as largely addressed but historically caused patient loss and timing shifts). - Potential payer access headwinds (step edits, reimbursement complexity), which analysts referenced. - Gross-to-net and product-mix pressure (non-GAAP gross margin down ~230 bps due to mix). - Execution risk in scaling a much larger sales force (ramp timing, productivity variability). - Competitive dynamics in specialty spaces and any unanticipated access restrictions that could impact uptake.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 7, 2026 | $1.82 est $1.67 | $266.0M est $260.1M | −8.3% |
| May 8, 2026 | $1.68 est $0.96 | $237.5M est $207.6M | −6.2% |
| Feb 27, 2026 | $2.33 est $2.04 | $247.1M est $231.1M | −2.5% |
| Nov 7, 2025 | $2.04 est $1.74 | $227.8M est $232.2M | −1.4% |
| Aug 8, 2025 | $1.80 est $1.38 | $211.4M est $208.8M | +23.0% |
| May 9, 2025 | $1.70 est $1.38 | $197.1M est $188.7M | −12.9% |
| Feb 28, 2025 | −$0.55 est $0.29 | $190.6M est $170.0M | +7.1% |
| Nov 8, 2024 | $1.34 est $1.09 | $148.3M est $175.1M | +5.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
ANI Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for ANI Pharmaceuticals is $105.78, +43.7% from the last close, from 8 firms rating the stock in the last 90 days.
$105.78consensus 12-month target, +43.7% from the last close
Now $73.59Avg $105.78
Low $85High $121
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 23 | Oppenheimer | $85 | +15.5% |
| Sep 21 | H.C. Wainwright | $121 | +64.4% |
| Sep 9 | Leerink Partners | $104 | +41.3% |
| Aug 25 | Barclays | $100 | +35.9% |
| Aug 11 | H.C. Wainwright | $121 | +64.4% |
+0.6%average 20-day move after past Neutral readings
+12.9%average move over the next 20 trading days in the last 5 years
±2.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
ANI Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, ANI Pharmaceuticals averaged +12.9% across the last 5 years, rising in 5 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +3.7% | 4 of 5 |
| Next 10 trading days | +4.9% | 4 of 5 |
| Next 15 trading days | +15.7% | 5 of 5 |
| Next 20 trading days | +12.9% | 5 of 5 |
| Next 30 trading days | +2.6% | 2 of 5 |
For scale, ANIP’s typical 20-trading-day move in either direction is about 6.4%.
ANI Pharmaceuticals market cap and key statistics
ANI Pharmaceuticals’s market cap is $1.67B, with a P/E ratio of 15.6 and revenue of $978.4M over the last twelve months.
Valuation
- Market cap
- $1.67B
- P/E ratio
- 15.6
- Forward P/E
- 7.1
- EPS, TTM
- $4.62
- Gekko Fair Value
- $123.93
Trading
- Volume
- 315,781
- Avg volume, 20 days
- 422,390
- 52-week high
- $97.00
- 52-week low
- $69.58
- Shares outstanding
- 22.96M
Financials
- Revenue, TTM
- $978.4M
- Profit margin
- 11.1%
- Return on equity
- 20.5%
- Quarterly earnings growth, YoY
- +191.1%
Risk and income
- Beta
- 0.50
- Typical daily move
- ±2.8%
- Typical 20-day move
- ±6.4%
ANI Pharmaceuticals stock news this week
Coverage of ANI Pharmaceuticals this week reads positive: 3 positive, 2 neutral and 0 negative headlines.
- ANI Pharmaceuticals reports Phase 4 eye-implant trial met both endpointsMugglehead Investment Magazine, Oct 12
- ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual MeetingGlobeNewswire, Oct 12
- ANI Pharmaceuticals Q3 2026 Earnings Date and EstimatesMarketBeat, Oct 11
- ANI Pharmaceuticals, Inc. (ANIP) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Oct 8
- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Consensus Price Target of $98.00 According to AnalystsMarketBeat, Oct 8
- Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH)Defense World, Oct 6
ANI Pharmaceuticals peers
ANI Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
ANI Pharmaceuticals stock FAQ
What is ANI Pharmaceuticals’s market cap?
ANI Pharmaceuticals’s market cap is $1.67B at the Oct 12, 2026 close of $73.59, with 22.96M shares outstanding. The shares trade on a P/E ratio of 15.6.
What is the ANI Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for ANI Pharmaceuticals is $105.78, +43.7% from the last close. Of the 8 firms that rated the stock in the last 90 days, 6 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is ANI Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate ANI Pharmaceuticals is undervalued: the Oct 12, 2026 close of $73.59 is 40.6% below Gekko Fair Value of $123.93. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does ANI Pharmaceuticals report earnings next?
ANI Pharmaceuticals is expected to report on Nov 6, 2026, before the market opens (25 days away). Analysts expect earnings of $2.18 per share on revenue of $280.3M. ANI Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 8.4% on average across the report.
What is ANI Pharmaceuticals’s 52-week high and low?
ANI Pharmaceuticals’s 52-week high is $97.00 and its 52-week low is $69.58; it closed at $73.59 on Oct 12, 2026, −18.9% over the past year. Over the last five years the shares peaked at $99.50 on Sep 10, 2025.
Is ANI Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See ANI Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.